Our take
Levita's magnetic approach is a narrower surgical robotics bet than full multiport systems from Intuitive-scale peers, which can be an advantage in high-volume laparoscopic cases.2,1
Commercial evidence is still earlier than large soft-tissue robot makers, so deployment proof matters more than brand awareness today.3
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Levita and what it's for
Hospitals and ambulatory surgery centers performing high-volume laparoscopic cases such as gallbladder surgery are the core buyers.2,1
Latin American and US sites are part of Levita's expansion, including a Miami hub.4
History
Dr. Alberto Rodriguez-Navarro founded Levita Magnetics and serves as CEO. The company is based in Mountain View, California.3,1
Levita raised $26 million in a Series C in 2022 to advance MARS and has raised more than $50 million overall, with a further growth round reported in 2026.3,6
MARS magnetic surgery
MARS combines magnetic surgical tools with robotic assistance so surgeons can reduce incisions in laparoscopic procedures.1,2
In 2023 the company won FDA clearance for the MARS system. It later reported AI-guided autonomous camera assistance in a landmark case in Santiago, Chile.2,1
Pricing
Levita does not publish capital or per-procedure prices on its public site. Hospital buyers negotiate through the company's commercial team.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Levita wins or loses |
|---|---|---|---|---|
| Levita Magnetics | MARS magnetic-assisted robotic surgery platform1 | Quote-only capital and procedure pricing1 | FDA-cleared MARS system with US and Latin America sites2 | Magnetic-assisted laparoscopic robotics rather than a full multiport console |
| Moon Surgical | Maestro bedside assistant with ScoPilot AI camera control15 | Not published8 | FDA cleared in 2024; dataset of more than 3,000 procedures7,15 | Moon Surgical wins on soft-tissue assistance with Maestro. Levita wins on magnetic port reduction. |
| Distalmotion (DEXTER) | DEXTER soft-tissue surgical robot with a small, mobile footprint10 | Not published10 | Almost 3,000 patients treated; three US clearances10 | Distalmotion wins on Dexter as a broader soft-tissue robot. Levita wins on magnet-focused MIS workflows. |
| CMR Surgical (Versius) | Versius Plus modular surgical robot11 | Not published11 | 45,000 cases worldwide; FDA 510(k) for gallbladder removal11 | CMR wins on Versius multiport robotics. Levita wins on a narrower magnetic approach. |
| Stereotaxis | Genesis robotic magnetic navigation and MAGiC catheters14 | Capital system sale, plus per-procedure disposables, service, and software updates12 | More than 100,000 patients treated at over 100 hospitals13 | Stereotaxis wins on magnetic cardiac ablation. Levita wins on laparoscopic general surgery magnets. |
Limits
Pricing is not public.1
Indication coverage and hospital credentials still limit how widely MARS is used versus general-purpose surgical robots.2
Revenue is not disclosed. Datanyze estimates about $11.3 million for 2025. This is an estimate, not a reported figure.5
What customers say
Where it helps
High-volume laparoscopic programs that want fewer ports may evaluate MARS before a full multiport robot.2
Systems already studying magnetic surgery tools have a shorter path to adoption.1
Where it falls short
Hospitals wanting a broader soft-tissue robot should look at Distalmotion or Moon Surgical's assistant-style systems.
Leadership

Alberto Rodriguez-Navarro
Founder and CEODr. Rodriguez-Navarro founded Levita Magnetics and leads development of its MARS magnetic surgery platform.3
Sources
- Levita Magnetics, Homepage, accessed November 5, 2026
- Levita Magnetics, Levita wins FDA clearance for MARS system, accessed November 5, 2026
- Levita Magnetics, Levita secures $26M to advance MARS, accessed November 5, 2026
- Refresh Miami, Levita Magnetics opens Miami hub, accessed November 5, 2026
- Datanyze, Levita Magnetics company profile, accessed November 5, 2026
- PitchBook, Levita Magnetics profile, accessed November 5, 2026
- Sofinnova Partners, Moon Surgical receives second FDA clearance, covering its commercial Maestro surgical robotics system, June 4, 2024, accessed November 3, 2026
- Moon Surgical, Homepage, accessed November 3, 2026
- PR Newswire, Moon Surgical and KARL STORZ announce strategic commercial collaboration, July 22, 2026, accessed November 3, 2026
- Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026
- CMR Surgical, Home page, accessed November 1, 2026
- Stereotaxis, Form 10-K for 2025, accessed November 1, 2026
- Stereotaxis, Investor relations overview, accessed October 31, 2026
- Stereotaxis, Products, accessed October 31, 2026
- PR Newswire, Moon Surgical expands Maestro platform into a multi-model physical AI platform with software version 2.7, June 9, 2026, accessed November 3, 2026


